Minimal Change Disease Associated With Durvalumab.
作者信息
Toda Masataro G, Fujii Kentaro, Kato Ai, Yoshifuji Ayumi, Komatsu Motoaki, Amino Yoshiaki, Kitazono Satoru, Hashiguchi Akinori, Ryuzaki Munekazu
机构信息
Division of Nephrology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
Department of Respiratory Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
出版信息
Kidney Int Rep. 2021 Sep 1;6(10):2733-2734. doi: 10.1016/j.ekir.2021.08.021. eCollection 2021 Oct.
Abstract
摘要
相似文献
1
Minimal Change Disease Associated With Durvalumab.与度伐利尤单抗相关的微小病变病
Kidney Int Rep. 2021 Sep 1;6(10):2733-2734. doi: 10.1016/j.ekir.2021.08.021. eCollection 2021 Oct.
2
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.度伐利尤单抗单药或联合替西木单抗治疗 PD-L1 低表达/阴性复发性或转移性头颈部鳞状细胞癌患者的安全性和有效性：Ⅱ期 CONDOR 随机临床试验。
JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628.
3
Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma.300毫克单剂量曲美木单抗联合度伐利尤单抗1500毫克每4周一次（STRIDE方案）用于不可切除肝细胞癌患者的群体药代动力学和暴露-反应分析
J Clin Pharmacol. 2023 Nov;63(11):1221-1231. doi: 10.1002/jcph.2288. Epub 2023 Jun 22.
4
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).根治性放化疗和度伐利尤单抗巩固治疗后进展的局部晚期非小细胞肺癌的后续治疗：一项多中心回顾性分析（TOPGAN 2021-02）。
Cancer Chemother Pharmacol. 2023 Jul;92(1):29-37. doi: 10.1007/s00280-023-04547-2. Epub 2023 May 27.
6
Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8 Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results.新辅助度伐利尤单抗单药或联合替西木单抗治疗口咽癌患者的 CD8 肿瘤淋巴细胞密度、安全性和有效性的影响：CIAO 试验结果。
Clin Cancer Res. 2020 Jul 1;26(13):3211-3219. doi: 10.1158/1078-0432.CCR-19-3977. Epub 2020 Apr 8.
7
Durvalumab activity in previously treated patients who stopped durvalumab without disease progression.在未发生疾病进展的情况下停用 durvalumab 的经治患者中的 durvalumab 活性。
J Immunother Cancer. 2020 Aug;8(2). doi: 10.1136/jitc-2020-000650.
8
Evaluation of Durvalumab-induced Lung Toxicity Using a Spontaneous Reporting Database.使用自发报告数据库评估度伐利尤单抗引起的肺部毒性。
Anticancer Res. 2022 Jul;42(7):3575-3582. doi: 10.21873/anticanres.15844.
9
Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.根治性放疗联合或不联合 durvalumab 巩固治疗后，非小细胞肺癌患者低剂量照射区间质性肺病进展的临床特征和危险因素。
Radiat Oncol. 2023 May 22;18(1):87. doi: 10.1186/s13014-023-02276-7.
10
Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab.不能手术的 III 期非小细胞肺癌患者同步放化疗后序贯 durvalumab 维持治疗的血液参数和体重的纵向变化。
BMC Cancer. 2022 Mar 24;22(1):317. doi: 10.1186/s12885-022-09395-6.
引用本文的文献
1
Onconephrology 2022: An Update.《Onconephrology 2022：更新》。
Kidney360. 2023 Feb 1;4(2):258-271. doi: 10.34067/KID.0001582022. Epub 2022 Dec 9.
2
Glomerular diseases after immune checkpoint inhibitors use: What do We know so far?免疫检查点抑制剂使用后的肾小球疾病：我们目前了解多少？
Ren Fail. 2022 Dec;44(1):2046-2055. doi: 10.1080/0886022X.2022.2147439.
3
Does treating with anti-PD-1 to improve glomerular health come without a cost?使用抗PD-1治疗来改善肾小球健康会没有代价吗？
J Clin Invest. 2022 Nov 15;132(22):e164747. doi: 10.1172/JCI164747.
4
Adverse Renal Effects of Anticancer Immunotherapy: A Review.抗癌免疫疗法的肾脏不良反应：综述
Cancers (Basel). 2022 Aug 23;14(17):4086. doi: 10.3390/cancers14174086.
本文引用的文献
1
Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020.免疫检查点抑制剂相关肾毒性：2020 更新版。
Kidney360. 2020 Jan 14;1(2):130-140. doi: 10.34067/KID.0000852019. eCollection 2020 Feb 27.
2
Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity?接受检查点抑制治疗的患者发生微小病变性肾病：是肾脏自身免疫的另一种表现形式吗？
Cancer Rep (Hoboken). 2020 Oct;3(5):e1250. doi: 10.1002/cnr2.1250. Epub 2020 Jun 29.
3
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.
4
Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases.癌症免疫疗法相关肾病综合征：2 例报告。
Am J Kidney Dis. 2017 Oct;70(4):581-585. doi: 10.1053/j.ajkd.2017.04.026. Epub 2017 Jun 23.
5
Paraneoplastic nephrotic syndrome in patients with lung cancer.肺癌患者的副肿瘤性肾病综合征
Intern Med. 2009;48(20):1817-20. doi: 10.2169/internalmedicine.48.2089. Epub 2009 Oct 15.
Zotero 插件